Beauty Health (SKIN) to Release Quarterly Earnings on Wednesday

Beauty Health (NASDAQ:SKIN) is anticipated to issue its quarterly earnings data after the market closes on Wednesday, March 12th. Analysts expect the company to announce earnings of ($0.10) per share and revenue of $78.02 million for the quarter. Parties interested in listening to the company’s conference call can do so using this link.

Beauty Health Price Performance

Shares of NASDAQ:SKIN opened at $1.29 on Tuesday. The company’s fifty day moving average price is $1.59 and its 200-day moving average price is $1.58. The firm has a market capitalization of $159.50 million, a price-to-earnings ratio of -3.06 and a beta of 0.84. Beauty Health has a one year low of $0.91 and a one year high of $5.17. The company has a debt-to-equity ratio of 9.23, a current ratio of 6.56 and a quick ratio of 5.57.

Analyst Ratings Changes

Separately, Canaccord Genuity Group increased their price target on shares of Beauty Health from $1.25 to $1.75 and gave the stock a “hold” rating in a report on Wednesday, November 13th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and one has issued a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $2.55.

About Beauty Health

The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health.